103 related articles for article (PubMed ID: 8692551)
1. Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis.
du Bois A; Vach W; Kiechle M; Cramer-Giraud U; Meerpohl HG
Oncology; 1996 Jun; 53 Suppl 1():46-50. PubMed ID: 8692551
[TBL] [Abstract][Full Text] [Related]
2. The severity and pattern of emesis following different cytotoxic agents.
Martin M
Oncology; 1996 Jun; 53 Suppl 1():26-31. PubMed ID: 8692547
[TBL] [Abstract][Full Text] [Related]
3. Pattern of carboplatin-induced emesis. The German Ondansetron Study Group.
du Bois A; Vach W; Cramer-Giraud U; Thomssen C; Glaubitz M; Fiola M
Anticancer Drugs; 1995 Oct; 6(5):645-51. PubMed ID: 8845474
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
Italian Group For Antiemetic Research
J Clin Oncol; 2004 Feb; 22(4):725-9. PubMed ID: 14966097
[TBL] [Abstract][Full Text] [Related]
5. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
Ossi M; Anderson E; Freeman A
Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
[TBL] [Abstract][Full Text] [Related]
6. Serotonin mechanisms in chemotherapy-induced emesis in cancer patients.
Cubeddu LX
Oncology; 1996 Jun; 53 Suppl 1():18-25. PubMed ID: 8692546
[TBL] [Abstract][Full Text] [Related]
7. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Hickok JT; Roscoe JA; Morrow GR; King DK; Atkins JN; Fitch TR
Cancer; 2003 Jun; 97(11):2880-6. PubMed ID: 12767103
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy.
du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR
Oncology; 1997; 54(1):7-14. PubMed ID: 8978585
[TBL] [Abstract][Full Text] [Related]
9. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis.
Sorbe BG; Berglind AM; Andersson H; Boman K; Högberg T; Hallgren M; Schmidt M
Cancer; 1998 Sep; 83(5):1022-32. PubMed ID: 9731907
[TBL] [Abstract][Full Text] [Related]
10. The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens.
du Bois A; Vach W; Siebert C; Holy R; Ledergerber M; Wechsel U; Kriesinger-Schroeder H
Support Care Cancer; 1997 May; 5(3):212-8. PubMed ID: 9176967
[TBL] [Abstract][Full Text] [Related]
11. Management of cisplatin-induced delayed emesis.
Hesketh P
Oncology; 1996 Jun; 53 Suppl 1():73-7. PubMed ID: 8692555
[TBL] [Abstract][Full Text] [Related]
12. Management of other non-cisplatin-induced emesis.
Schmoll HJ; Casper J
Oncology; 1996 Jun; 53 Suppl 1():51-5. PubMed ID: 8692552
[TBL] [Abstract][Full Text] [Related]
13. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R
Oncology; 1991; 48(5):403-5. PubMed ID: 1836058
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
15. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced alterations of serotonin metabolism in patients with or without emesis following chemotherapy.
Dubois A; Siebert C; Vach W; Kriesingerschroeder H
Oncol Rep; 1995 Sep; 2(5):839-42. PubMed ID: 21597827
[TBL] [Abstract][Full Text] [Related]
17. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
18. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
20. Delayed nausea and vomiting from carboplatin doublet chemotherapy.
Waqar SN; Mann J; Baggstrom MQ; Waqar MA; Chitneni P; Williams K; Gao F; Morgensztern D; Govindan R
Acta Oncol; 2016 Jun; 55(6):700-4. PubMed ID: 27145068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
